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Background: Isolated systolic hypertension is a highly prevalent disease among the elderly. The little available
evidence on the efficacy of nitrates for treating the disease is based on small experimental studies.
Methods/design: We performed a multicenter, randomized, double-blind, phase III, placebo-controlled trial in 154
patients aged over 65 years with refractory isolated systolic hypertension. Patients were randomized to placebo or
40 mg/day of extended-release isosorbide mononitrate added to standard therapy and titrated to 60 mg/day at
week 6 if blood pressure exceeded 140/90 mmHg.
The primary objective was to assess the effect on clinical pulse pressure of extended-release isosorbide mononitrate
added to standard therapy in patients aged over 65 years with refractory isolated systolic hypertension after
3 months of treatment.
The secondary objectives were as follows: to quantify the effect of adding the study drug on central blood pressure
and vascular compliance using the augmentation index and pulse wave velocity; to evaluate the safety profile by
recording adverse effects (frequency, type, severity) and the percentage of patients who had to withdraw from the
trial because of adverse events; to quantify the percentage of patients who reach a clinical systolic blood pressure
<140 mmHg or <130 mmHg measured by ambulatory blood pressure monitoring; and to quantify the change in
pulse pressure measured by ambulatory blood pressure monitoring.
Discussion: Few clinical trials have been carried out to test the effect of oral nitrates on isolated systolic hypertension,
even though these agents seem to be effective. Treatment with extended-release isosorbide mononitrate could
improve control of systolic blood pressure without severe side effects, thus helping to reduce the morbidity and
mortality of the disease.
Trial registration: EUDRACT Number: 2012-002988-10
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Hypertension is responsible for many deaths worldwide
[1,2]. It is very prevalent in Spain and is estimated to
affect more than 25% of adults [3,4]. In the United
States, more than 60% of people aged over 65 years are
hypertensive. The most prevalent type of hypertension is
isolated systolic hypertension (ISH), which has a fre-
quency that increases with age and can reach over 80%
in octogenarian patients [5]. Loss of arterial elasticity ac-
companied by increased arterial stiffness is the main
pathogenic mechanism in ISH, which is characterized by
high systolic blood pressure (SBP) (≥140 mmHg) and
normal diastolic blood pressure (DBP) (<90 mmHg),
with a consequent increase in differential pressure, or
pulse pressure (PP), the main predictor of cardiovascular
complications in older people [6]. The mechanism
responsible for the decrease in arterial compliance is the
subject of debate and has been considered to be purely
structural (that is, secondary to the calcification pro-
duced by age in the walls of large arteries) or partly
functional (that is, due to endothelial dysfunction and
increased smooth muscle tone).
Treating ISH is beneficial, as it can reduce both cardio-
vascular morbidity and total mortality [7], even in much
older people [8]. Besides the widespread recommendation
to reduce SBP to less than 140 mmHg, there is no evidence
from clinical trials to support this recommendation in older
people, since none of the studies demonstrating a benefit
included patients with an SBP between 140 and 160 mmHg
[9]. No first-line antihypertensive treatments can produce a
clinically relevant reduction in arterial compliance and,
therefore, PP, [10,11], with the result that treatment options
are limited. The decrease in SBP is accompanied by de-
clines in DBP that can compromise coronary perfusion and
increase the risk of coronary complications, which is again
a limiting factor for current treatments. It seems reasonable
to assume that a drug that decreases both SBP and PP
could have additional benefits in the treatment of ISH. The
value of such an approach could be proven in the short
term by demonstration of changes in vascular function pa-
rameters (augmentation index (AI) and pulse wave velocity
(PWV)) and in the long term by documenting a reduction
in cardiovascular morbidity and mortality.
Nitrates have been used for many years to treat pa-
tients with angina pectoris, acute coronary syndrome,
and acute lung edema. These agents are not generally
used to treat hypertension, except in emergency cases, in
which case they are used intravenously to produce a
rapid decrease in blood pressure, although tachyphylaxis
occurs within a few days of treatment. All nitrates, as
donors of nitric oxide (NO), produce intense arterial
vasodilation associated with direct effects on smooth
muscle cells, by activating guanylyl cyclase to form
cGMP, which inhibits calcium entry into the cell. The mostcommon adverse events are headache and hypotension, al-
though dizziness, nausea, fatigue, weakness, and tachycar-
dia can also be observed.
Currently available tools enable us to evaluate vascular
function and central hemodynamics non-invasively. Cen-
tral blood pressure (CBP) can be measured in larger
arteries using pulse wave analysis, and available data sug-
gest a closer relationship between CBP and cardiovascular
morbidity and mortality [12]. Additionally, PWV, which is
the best parameter for measuring arterial elasticity [13,14],
can be measured non-invasively and provides an accessible
and exhaustive evaluation of arterial stiffness, which is the
underlying pathogenic mechanism of ISH [15].
Our literature review revealed only five mini-trials
assessing the effect of nitrates on blood pressure (BP)
and control of ISH. Sample sizes were small and the
studies were not performed in the context of refractory
ISH [16-20]. The results provide some evidence of the
possible use of exogenous NO donors to decrease the
reflected wave amplitude and PP [16-22]. Use of nitrates
could have a beneficial effect on the control of ISH (as
SBP falls with almost no change in DBP), with a possible
reduction in cardiovascular morbidity and mortality.
Therefore, we designed a study to evaluate the effect on
PP and vascular function (CBP, AI, and PWV) of the
addition of extended-release isosorbide mononitrate to
standard treatment in older patients with refractory ISH.
Refractory hypertension is defined as uncontrolled hyper-
tension in patients using three or more antihypertensive
drugs (one of which is a diuretic) at the maximum dosage;
we changed our protocol to include patients receiving low
doses of diuretic and maintaining at least two more drugs,
since most patients never use diuretics at the maximum
dosage (for example, hydrochlorothiazide at 50 mg/day).
If a beneficial effect is demonstrated, a study of mor-
bidity and mortality would be justified.
Hypothesis
The addition of extended-release isosorbide mononitrate to
standard antihypertensive treatment in patients with refrac-
tory ISH produces a positive effect on vascular function,
resulting in reduced PP and improved CBP, AI, and PWV.
Aims
The primary objective of our study was to compare the ef-
fect of extended-release isosorbide mononitrate on clinical
PP with that of a placebo, in addition to the standard
treatment, in patients over 65 with refractory ISH after
3 months of treatment.
The secondary goals were as follows:
1. To quantify the effect of extended-release isosorbide
mononitrate on vascular function (estimated using
CBP, AI, and PWV).
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frequency, type, and severity of adverse events and
the percentage of patients who had to withdraw
from the study because of adverse events, in
particular headache and orthostatic hypotension.
3. To determine the percentage of patients who reach
clinical SBP <140 mmHg in both treatments groups.
4. To determine the percentage of patients who reach
a 24-hour mean SBP <130 mmHg (measured using
ambulatory blood pressure monitoring (ABPM)) in
both treatment groups.
5. To measure the change in PP using ABPM.Methods/design
Ours is a phase III, multicenter, randomized, double-
blind, placebo-controlled trial performed in several pri-
mary care centers in the Regional Community of Madrid
and in Hospital La Princesa, Madrid. The trial is regis-
tered in the EU Clinical Trials Register (EUDRACT
Number: 2012-002988-10), and the protocol was ap-
proved by the Clinical Research Ethics Committee of the
Regional Community of Madrid.
The study was designed to evaluate the efficacy and
safety of a marketed drug in a therapeutic indication dif-
ferent from that for which it is approved. The objective
of the study was to evaluate, after 3 months of appropri-
ate treatment, the effect of adding extended-release iso-
sorbide mononitrate to standard treatment in patients
with resistant ISH. No recommendations have been
made on the treatment of these patients; therefore, weble 1 Inclusion and exclusion criteria
clusion criteria
ed 65 or over
fractory ISH: SBP ≥140 mmHg and DBP <90 mmHg and SBP in ABPM ≥130
spite treatment with three drugs at maximum dosage, one of them diuret
least one month before the start
od adherence to treatment, defined as a good response to all questions o
orisky-Green’s test
e expectancy greater than 1 year
gning the informed consent
ility to understand study procedures and to comply with them for the ent
ngth of the study
tients are included if they meet all the inclusion criteria and none of the exclusio
PM: ambulatory blood pressure monitoring, DBP: diastolic blood pressure, ISH: is
odification of diet in renal disease, SBP: systolic blood pressure.designed a study to compare the net effect of the study
drug with that of placebo.
The study began in January 2013 and is ongoing
Participants
The study population comprises patients aged ≥65 years
of both genders attended at primary care centers or at
the Hypertension Unit of Hospital La Princesa. All pa-
tients give their written informed consent to participate
in the study. Patients are included if they meet all the in-
clusion criteria and none of the exclusion criteria. Table 1
shows the inclusion and exclusion criteria .
Variables
Variables reported for trial participants include the
following:
1. Demographic characteristics: sex, age, height,
weight, body mass index, waist circumference, and
smoking and drinking habits, at screening.
2. Antihypertensive treatment and concomitant
treatments, at screening.
3. Medical history: presence of macrovascular or
microvascular disease and diabetes mellitus or
dyslipidemia.
4. Laboratory tests: hematology and biochemistry with
kidney and liver function markers to assess that the
patient meets all the inclusion criteria (screening visit).
5. BP measurement at baseline, 6 weeks, and
completion (SBP, DBP, PP, and heart rate (mean of 3)
while seated and 1 minute after standing).Exclusion criteria
Current treatment with nitrates, intolerance to them or
contraindication to their use
mmHg,
ic, during
Concomitant treatment with phosphodiesterase 5 inhibitors
SBP ≥180 mmHg
f Permanent atrial fibrillation
Secondary hypertension
Congestive heart failure, grade III-IV NYHA
Chronic kidney disease with glomerular filtration rate
≤30 ml/min, estimated by MDRD
ire
Liver insufficiency
Active cancer
Anemia ≤8 g/dl
Simultaneous participation in another clinical trial
Not signing the informed consent
Any other circumstance that, according to the research
criteria, advises against the inclusion to the study
n criteria.
olated systolic hypertension, NYHA: New York heart association, MDRD:
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before patients take their medication.
6. 24-hour ABPM (Spacelabs device, OSI systems
company, US; www.spacelabshealthcare.com/): mean
of SBP, DBP, heart rate, and PP during activity and at
rest (baseline and completion). Patients take their
antihypertensive medication as usual.
7. CBP, PWV, and AI at visits 1 and 3 (measured with
the patient lying supine using a Sphygmocor device,
AtCor Medical, Australia; www.atcormedical.com/).
8. Adherence to treatment (Morisky-Green test) at
screening and at visits two and four.
9. Side effects: any adverse event during administration
of the study drug, in particular headache and
orthostatic hypotension.
Randomization, blinding, and assignment to treatment
groups
Subject numbers are assigned sequentially as each pa-
tient enters the study. Subjects are assigned to the study
drug through a randomization schedule based on the
randomization plan. The study drug is stored under the
conditions specified on the label in a locked, safe area of
the pharmacy department to prevent unauthorized
access.
Both the study drug and the placebo are indistinguish-
able; they are manufactured by the same company and
are similar in appearance, organoleptic characteristics,
and presentation.
In the event of an emergency, the investigator decides
whether it is necessary to unblind the subject’s treatment
assignment using the unblinding envelopes provided to
the hospital and/or pharmacy. If unblinding is necessary,
the investigator or study pharmacist must record the
reason for unblinding, as well as the date and time of
the event.
During the study, the events considered sufficient rea-
son for unblinding are as follows: admission to hospital
or visit to the emergency department related to the
study drug. The patients can be removed from the study
without unblinding in the following circumstances: with-
drawal of consent, major adverse event(s), ineligibility
(arising either during the study or retrospectively after
having been overlooked at screening), significant proto-
col deviation, disease progression requiring discontinu-
ation of the study medication or inability to continue to
comply with study procedures, loss to follow-up, or
death. Each participant has the right to withdraw from
the study at any time, for any reason, and with no reper-
cussions for his/her medical care.
In the case of unblinding, the analyses are based on an
intent-to-treat population, which includes all random-
ized subjects. Because the percentage of lost participants
was predicted in the calculation of sample size, lostpatients need not be replaced during follow-up. The per-
son analyzing the results remains blind to the patient’s
group.
Trial intervention
When all of the procedures at the inclusion visit are per-
formed, the patients are sent to the investigator respon-
sible for assessing vascular function (PWV, AI, and
CBP), randomization, and delivery of the study medica-
tion (12-week supply). Vascular function parameters are
measured by the same trained investigator to ensure
consistency and homogeneity.
Before administration of the drug, the investigator ex-
plains the most common adverse events (headache and
orthostatic hypotension) to the patient.
After randomization, a single 40-mg dose of extended-
release isosorbide mononitrate is administered between
9:30 and 10:30 am during the first 6 weeks. Study pa-
tients attend three visits after randomization. The first is
at 6 weeks from baseline, when clinical parameters are
assessed. These include BP (seated and standing), resting
pulse, and the Morisky-Green test. All adverse events
are recorded, regardless of their relationship to the study
medication. If the objective (SBP <140 mmHg) is not
reached, the dose is titrated to 60 mg/d (single dose);
otherwise, the 40-mg dose is maintained.
After 12 weeks of treatment, the study is considered to
have finished, except in the case of patients who withdraw
prematurely. At the final visit, the parameters recorded
are PP, SBP, DBP, heart rate and ambulatory BP. Compli-
ance is also evaluated using the Morisky-Green test, and
the investigator questions the patient about adverse
events, orthostatic hypotension, and other treatments
taken during the study. Vascular function parameters
(CBP, AI, and PWV) are measured between 2 and 5 days
before the final visit while the patient is still taking the
medication.
Figure 1 shows the study flow-chart.
Evaluation of effectiveness
The study drug is considered effective if PP decreases
significantly with respect to placebo according to the
primary objective.
Secondary efficacy is assessed based on the improve-
ment in vascular function parameters, the percentage of
patients achieving control of BP at the clinic and with
ABPM, and the change in PP measured by ABPM. All
objectives are measured based on the comparison of
values from the baseline and final visits.
Ethics
The planning and conduct of this trial are subject to na-
tional legislation. The trial is performed in accordance
with the Guidelines of the World Medical Association
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RECRUITMENT OF 
PATIENTS
Patients 65 or over with resistant 
ISH who meet all inclusión and 
none of exclusion criteria.
Measurement of BP and AMBP.
Baseline measurements of 
vascular function: AI, PWV and 
CBP.
Active group: 40mg/day of 
extended release isosorbide 
mononitrate
Control group: pill of placebo 
simulating extended release 
isosorbide mononitrate
- If BP <140/90: continue with 
40mg/day of extended release 
isosorbide mononitrate.
-If BP >140/90: titration to 
60mg/day of extended release 
isosorbide mononitrate.
- If BP <140/90: continue with the 
same dose of placebo. 
- If BP >140/90: titration to 
placebo simulating 60mg/day of 
extended release isosorbide 
mononitrate.
Final measurements of vascular 
function: AI, PWV and CBP.
Final visit: BP, AMBP, adverse 
effects, Morinsky-Green, 
concurrent medication.
DATA ANALYSIS
7 +/- 3 days
RANDOMIZATION
Control visit: 6 weeks after randomization
12 weeks
Figure 1 Study flow-chart.
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lines of GCP (CPMP/ICH/135/95), and the stipulations
of national drug and data protection laws and other ap-
plicable regulatory requirements.
The investigator is responsible for ensuring that no pa-
tient undergoes any study-related examination or activity
before either the patient or the legal guardian has signed an
informed consent document. Detailed information is pro-
vided to the patient/legal guardian before consent is given.
The investigator must inform the patient of the aims,
methods, anticipated benefits, and potential hazards of the
study, including any discomfort it may entail. The investi-
gator must inform patients that in providing informedconsent, they are giving permission for representatives of
the trial site coordinating investigator or regulatory au-
thorities to inspect their medical records to verify the in-
formation collected. The patient must be given every
opportunity to clarify any points he/she does not under-
stand. Patients or legal guardians must sign and date the
informed consent form. Patients who refuse to give or
withdraw their written informed consent are either not in-
cluded or do not continue to participate in the study.
In accordance with Spanish legislation (RD 223/2004
of 6 February), a civil liability insurance policy has been
taken out to cover possible adverse events arising from
the study medication that could affect the trial subjects.
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The most common adverse events are headache, ortho-
static hypotension, somnolence, dizziness, and asthenia.
These generally disappear with continued treatment. Less
common or rare adverse events include bradycardia, an-
gina pectoris, acute hypotension and syncope, nausea,
vomiting, exfoliative dermatitis, allergic reactions, and
flushing. Overdose can produce hypotension, tachycardia,
cyanosis, shock, seizures, vomiting, agitation, respiratory
failure, bradycardia, and methemoglobinemia.
The period for reporting an adverse event starts when
the study drug is administered and ends with the last
follow-up visit. The association between an adverse event
and the trial medication must be classed as related or not
related to the study drug by a study physician.
Adverse events considered related to the study medi-
cation are monitored until resolution or until the event
is considered stable. All related adverse events that re-
sult in a participant’s withdrawal from the study or are
present at the end of the study should be monitored
until resolution. It is left to the investigator’s clinical
judgment whether or not an adverse event is of suffi-
cient severity to warrant the participant’s withdrawal
from treatment.
This study is performed without an external sponsor
under the coordination of the scientific committee and
under the supervision of a safety committee, which is
blind to the intervention. The safety committee is com-
posed of three physicians, each of whom is an expert in
hypertension. The committee also includes a biostatisti-
cian and expert in bioethics.
Sample size calculation
Sample size is predetermined based on the effect the
variable PP, which is the primary objective. According to
the results of the Starmans-Kool trial [17], the PP after
treatment could be 87 mmHg in the placebo group
and 79 mmHg in the experimental group, both with a
standard deviation of 16 mmHg. In order to obtain a
power of 80% to detect differences using a t test for
independent samples, with an α risk of 5%, the sample
size for each group must be 64 patients. Considering
losses of 20% of recruited individuals, which could weaken
the sample for some secondary objectives, we decided to
increase the sample size by this percentage, although all
the tests are performed by intent to treat. For this reason,
the final sample size for each group is 77 patients.
Statistical analysis
The statistical analysis will comprise the following parts:
1. In descriptive analysis of the sample, quantitative
variables will be expressed as measures of central
tendency (mean or median) and dispersion (standarddeviation or interquartile range) for symmetrical
distributions; normality will be tested using
Kolmogorov-Smirnov test. Appropriate transforma-
tions will be applied in cases of a non-normal distri-
bution. Qualitative variables will be expressed as
proportions with their standard error.
2. Baseline characteristics, especially those that could
influence the results, will be compared using the t
test or Mann–Whitney test for quantitative variables
and the Pearson chi-squared or Fisher exact test for
qualitative variables. The main variables that could
influence the result of this study at initiation are age,
PP, SBP, and DBP. In the case of inequality, these
factors will be treated as confounding variables in
the final efficacy analysis.
3. The differences between the means and their
confidence interval (CI), or the median ratio and
their CI, will be used as the main measure of the
effect. The relative risk, absolute risk reduction, and
relative risk reduction will be used as a measure of
the effect for the qualitative variables. A 95% CI will
be calculated for all estimations.
4. To control for possible confounding variables, linear
models or linear regression will be applied for
dependent quantitative variables and logistic
regression models for dependent qualitative variables.
5. In all the analyses, the null hypothesis tested will be the
lack of effect (difference of means = 0, RR = 1) between
the experimental and the control groups. Missing data
will be processed using a sensitivity analysis.
6. As this is a two-arm, placebo-controlled, parallel
study, no subgroups will be analyzed to measure
secondary endpoints and no interim analysis will be
performed.
Discussion
ISH remains difficult to control in many cases, despite the
availability of various types of appropriate medication; how-
ever, most are able to reduce SBP, albeit with a considerable
associated reduction in DBP. The consequent severe side
effects, such as reduced coronary perfusion and orthostatic
hypotension, limit treatment options.
Hypertension continues to be the most important car-
diovascular risk factor today, and cardiovascular illnesses
are the main cause of death in developed countries, es-
pecially among people over 65.
The results of our trial should demonstrate whether
treatment with isosorbide mononitrate improves not
only control of arterial pressure, but also vascular func-
tion in patients with refractory ISH. If our hypotheses
are proved, a clinical trial with morbidity and mortality
as the main end-points would be justified. Such a trial
could also be used to investigate the long-term effects of
this drug.
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nitrates in patients with ISH, even though these agents
seem to be effective and have been used over long periods
in the treatment of other illnesses, such as ischemic heart
disease, hypertensive emergency, or acute lung edema.
Our trial is performed on a collaborative basis between
the hospital (center for recruitment and vascular function
tests) and the primary care center, because most of these
patients have their main contact with the health service
through their primary care physicians. A collaboration of
this type makes it easier to reach patients and provides
more robust results with greater external validity.
Our study is subject to three limitations. First, poten-
tially high loss to follow-up because of non-fatal side ef-
fects; however, this is compensated for, as it was taken
into account in the sample size calculation. Second, in
the long term, patients could develop tolerance to ni-
trates, although this was not demonstrated in any of the
trials we reviewed. Finally, our trial was not designed to
demonstrate reductions in morbidity and mortality; ra-
ther, our main objective was to evaluate tolerance and
effects on some intermediate variables.
In conclusion, treatment of ISH with extended-release
isosorbide mononitrate could improve control of SBP
with minimal side effects, thus helping to reduce the
morbidity and mortality of the disease.
Trial status
The trial is in the recruitment phase.
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